Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
CPRIT awards supplemental product-development funding to eight companies; OncoResponse equity tranche contingent on clinical milestone
Summary
CPRIT approved supplemental awards for product development using a roughly $10 million carryover pool. The agency prioritized existing grantees; OncoResponse received a conditional equity tranche tied to a clinical milestone.
The oversight committee approved supplemental product-development awards for companies that already held active CPRIT grants, using a carryover pool of roughly $10 million.
Why this matters: The supplemental funding aims to accelerate commercialization activities and clinical progress for companies already in CPRIT’s portfolio. CPRIT approved advanced payments contingent on contract execution and tranche conditions.
What the product-development presentation said - Pool and approach: CPRIT staff used about $10 million of carryover from FY25 product-development funds to provide supplemental awards to existing CPRIT-funded companies. The RFA limited awards to a maximum total supplemental request (no single supplemental award above specified percentage rules for seed-stage recipients). - Selection: 23…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
